Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following investor and media conferences in September.
H.C. Wainwright 24th Annual Global Investment Conference
| Presentation Format: | Corporate Presentation |
| Date & Time: | September 13, 2022, at 11:00 AM ET |
| Location: | Lotte New York Palace Hotel |
| Webcast Link: | Here |
Baird’s 2022 Global Healthcare Conference
| Presentation Format: | Corporate Presentation |
| Date & Time: | September 14, 2022, at 3:10 PM ET |
| Location: | InterContinental New York Barclay |
| Webcast Link: | Here |
Cantor Cell and Genetic Medicines Conference
| Presentation Format: | Panel Discussion |
| Panel Title: | CAR-T and Beyond: What Are the Next Generation Cell Therapies? |
| Date & Time: | September 15, 2022, at 9:20 AM ET |
| Location: | Lotte New York Palace Hotel |
Company management will be available for 1×1 investor meetings during the Cantor and H.C. Wainwright events. Those interested in requesting a meeting during the conferences should contact their respective event representative.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL…
More than 50% of men now face erectile dysfunction after the age of 40. In…
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025)…
After six months of research on the ingredients and thousands of feedback from real consumers,…
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT InterventionsSOUTH SAN FRANCISCO, Calif.,…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
